Observational analysis tracks genomic antigen escape in multiple myeloma patients during T cell immunotherapy, suggesting acquired mutations.
Summary: In this issue of Blood Cancer Discovery, Papadimitriou and colleagues implement a temporal workflow to monitor genomic antigen escape during BCMA- or GPRC5D-directed immunotherapy. Using chemotherapy-induced mutational signatures as barcodes, they provide evidence that these mutations are acquired during therapy rather than being preexisting in newly diagnosed patients. See related article by Papadimitriou et al., p. XX .
No takes yet. Share an insight, caveat, or question.
Kauer et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: